BioLineRx Ltd.(BLRX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-12-31.

BioLineRx Ltd. (BLRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BLRX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $28.9m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), BioLineRx Ltd. reports quarterly revenue of $1.2M, net income of $-2.0M. BLRX trades on the Nasdaq exchange and files with the SEC under CIK 1498403. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BLRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioLineRx Ltd. directly from SEC EDGAR.